Product News
Zhonghan Biotech's Abemaciclib Intermediates: High-Quality Key Intermediates Empowering Efficient Synthesis of CDK4/6 Inhibitors
2026-03-04
As an orally highly selective CDK4/6 inhibitor, Abemaciclib is a core targeted drug for the treatment of HR+/HER2- breast cancer, widely used in the clinical treatment of locally advanced and metastatic breast cancer. Its synthesis chain has stringent requirements for the purity, stability and batch consistency of key intermediates, which directly determine the quality of active pharmaceutical ingredients (APIs) and the safety of preparations.